Breast Cancer

A drug supply agreement with Pfizer will enable Jiangsu Alphamab to study the combination of its dual-HER2 signal blocking drug, KNO26, and Ibrance.

The approval limits the drug's use to patients who are refractory or intolerant to standard-of-care treatments and contains warnings about the risk of interstitial lung disease.

Breast cancer patients with certain germline risk variants were more responsive to the chemotherapy combinations tested in a randomized trial.

A new study supports the development of BET inhibitors for MYCN-driven triple negative breast cancer as a single agent and in combination with a MEK inhibitor.

Researchers found that more than 3 percent of postmenopausal women with breast cancer but no other disease risk factors carried pathogenic variants. 

Radiation therapy did not appear to change the relationship between cancer risk and pathogenic variants in ATM, BRCA1/2, or CHEK2*1100delC.

Patients with luminal breast cancer subtypes may do just as well without anthracycline-based chemo and avoid unnecessary toxicities, a study showed.

The FDA had previously approved neratinib as an extended adjuvant therapy for patients with early-stage HER2-overexpressed or amplified breast cancer, following adjuvant treatment with trastuzumab.

The NDA, based on data from a randomized Phase II trial, is for the use of tucatinib combined with trastuzumab and capecitabine for HER2-positive breast cancer patients.

Using data from cancer registries, investigators saw apparent disparities in the surgical interventions and treatments used for breast cancer patients with inherited cancer risk.